{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T22:29:08Z","timestamp":1762554548042,"version":"build-2065373602"},"reference-count":18,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T00:00:00Z","timestamp":1749081600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","dldjournalonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Digestive and Liver Disease"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.dld.2025.04.036","type":"journal-article","created":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T07:21:48Z","timestamp":1747293708000},"page":"1411-1418","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Factors associated with response to filgotinib and the prognostic power of faecal calprotectin for ulcerative colitis in the phase 2b\/3 SELECTION trial"],"prefix":"10.1016","volume":"57","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1287-7075","authenticated-orcid":false,"given":"Edouard","family":"Louis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6807-9822","authenticated-orcid":false,"given":"Stefan","family":"Schreiber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1178-3536","authenticated-orcid":false,"given":"Tadakazu","family":"Hisamatsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6256-1204","authenticated-orcid":false,"given":"Toshifumi","family":"Hibi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-9363-6077","authenticated-orcid":false,"given":"Corinne","family":"Jamoul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-0990-8199","authenticated-orcid":false,"given":"Karine","family":"Muller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Virginia","family":"Taliadouros","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8556-1004","authenticated-orcid":false,"given":"Alessandra","family":"Oortwijn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2536-6618","authenticated-orcid":false,"given":"Laurent","family":"Peyrin-Biroulet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6914-3822","authenticated-orcid":false,"given":"Brian G.","family":"Feagan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.dld.2025.04.036_bib0001","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1001\/jama.2023.15389","article-title":"Ulcerative colitis in adults: a review","volume":"330","author":"Gros","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.dld.2025.04.036_bib0002","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1053\/j.gastro.2020.12.031","article-title":"STRIDE-II: an update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) initiative of the International Organization for the Study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD","volume":"160","author":"Turner","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2025.04.036_bib0003","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1093\/jcag\/gwad025","article-title":"Choosing therapies in ulcerative colitis","volume":"7","author":"Das","year":"2024","journal-title":"J Can Assoc Gastroenterol"},{"key":"10.1016\/j.dld.2025.04.036_bib0004","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1080\/03007995.2023.2194782","article-title":"The incidence of remission and indicators of inadequate response to advanced therapy in patients with ulcerative colitis: results from medical charts in the United Kingdom","volume":"39","author":"Lindsay","year":"2023","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.dld.2025.04.036_bib0005","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s12876-023-02675-w","article-title":"Identification of inadequate responders to advanced therapy among commercially-insured adult patients with Crohn's disease and ulcerative colitis in the United States","volume":"23","author":"Gibble","year":"2023","journal-title":"BMC Gastroenterol"},{"key":"10.1016\/j.dld.2025.04.036_bib0006","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1016\/S0140-6736(21)00666-8","article-title":"Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b\/3 double-blind, randomised, placebo-controlled trial","volume":"397","author":"Feagan","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.dld.2025.04.036_bib0007","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1002\/ueg2.12686","article-title":"Distinct trajectories of symptomatic response in ulcerative colitis during filgotinib therapy: a post hoc analysis from the SELECTION study","volume":"12","author":"Schreiber","year":"2024","journal-title":"United European Gastroenterol J"},{"key":"10.1016\/j.dld.2025.04.036_bib0008","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1093\/ecco-jcc\/jjad130","article-title":"Defining comprehensive disease control for use as a treatment target for ulcerative colitis in clinical practice: international Delphi consensus recommendations","volume":"18","author":"Schreiber","year":"2024","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.dld.2025.04.036_bib0009","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1093\/ibd\/izaa163","article-title":"Fecal calprotectin thresholds to predict endoscopic remission using advanced optical enhancement techniques and histological remission in IBD patients","volume":"27","author":"Cannatelli","year":"2021","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.dld.2025.04.036_bib0010","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1159\/000514196","article-title":"Optimal range of fecal calprotectin for predicting mucosal healing in patients with inflammatory bowel disease: a systematic review and meta-analysis","volume":"37","author":"Xiang","year":"2021","journal-title":"Visc Med"},{"key":"10.1016\/j.dld.2025.04.036_bib0011","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1093\/ecco-jcc\/jjy184","article-title":"Defining faecal calprotectin thresholds as a surrogate for endoscopic and histological disease activity in ulcerative colitis\u2013a prospective analysis","volume":"13","author":"Walsh","year":"2019","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.dld.2025.04.036_bib0012","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1097\/00054725-200606000-00013","article-title":"Role of fecal calprotectin as a biomarker of intestinal inflammation in inflammatory bowel disease","volume":"12","author":"Konikoff","year":"2006","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.dld.2025.04.036_bib0013","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/j.cgh.2013.07.022","article-title":"Histologic remission: the ultimate therapeutic goal in ulcerative colitis?","volume":"12","author":"Peyrin-Biroulet","year":"2014","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2025.04.036_bib0014","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1177\/2050640617752207","article-title":"Prognostic value of histological activity in patients with ulcerative colitis in deep remission: a prospective multicenter study","volume":"6","author":"Lobaton","year":"2018","journal-title":"United Eur Gastroenterol J"},{"key":"10.1016\/j.dld.2025.04.036_bib0015","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1038\/ajg.2012.301","article-title":"Prognostic value of serologic and histologic markers on clinical relapse in ulcerative colitis patients with mucosal healing","volume":"107","author":"Bessissow","year":"2012","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.dld.2025.04.036_bib0016","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1111\/apt.18158","article-title":"Long-term safety and efficacy of filgotinib for the treatment of moderately to severely active ulcerative colitis: interim analysis from up to 4 years of follow-up in the SELECTION open-label long-term extension study","volume":"60","author":"Feagan","year":"2024","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.dld.2025.04.036_bib0017","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1136\/flgastro-2015-100574","article-title":"What do patients want from their endoscopy experience? The importance of measuring and understanding patient attitudes to their care","volume":"7","author":"Tierney","year":"2016","journal-title":"Frontline Gastroenterol"},{"year":"2023","series-title":"Summary of product characteristics, Jyseleca","author":"Alfasigma","key":"10.1016\/j.dld.2025.04.036_bib0018"}],"container-title":["Digestive and Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865825007480?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865825007480?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T22:27:38Z","timestamp":1762554458000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1590865825007480"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":18,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S1590865825007480"],"URL":"https:\/\/doi.org\/10.1016\/j.dld.2025.04.036","relation":{},"ISSN":["1590-8658"],"issn-type":[{"type":"print","value":"1590-8658"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Factors associated with response to filgotinib and the prognostic power of faecal calprotectin for ulcerative colitis in the phase 2b\/3 SELECTION trial","name":"articletitle","label":"Article Title"},{"value":"Digestive and Liver Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dld.2025.04.036","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s), Alfasigma S.p.A. and Galapagos NV. Published by Elsevier Ltd on behalf of Editrice Gastroenterologica Italiana S.r.l.","name":"copyright","label":"Copyright"}]}}